Recent advances of selenized tubulin inhibitors in cancer therapy

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Cancer treatment faces challenges due to drug resistance and relapse.
• Tubulin inhibitors targeting mitosis are promising therapeutic agents.
• Selenium (Se) is an essential microelement with antioxidant roles and potential in cancer therapy.

Purpose of the Study:

• To review the latest research on selenized tubulin inhibitors in cancer therapy.
• To explore their mechanisms, categories, and biological activities.
• To provide a theoretical basis for developing novel selenized microtubule inhibitors.

Main Methods:

• Literature review of recent studies on selenized tubulin inhibitors.
• Analysis of the role of selenium incorporation in modifying tubulin inhibitor properties.
• Examination of biological activities and mechanisms of action.

Main Results:

• Selenium incorporation alters chemical properties, enhancing therapeutic potential.
• Selenized tubulin inhibitors demonstrate significant biological activities in preclinical studies.
• This approach offers a novel strategy to combat cancer resistance and relapse.

Conclusions:

• Selenized tubulin inhibitors represent a promising frontier in cancer treatment.
• Further research into their mechanisms and clinical applications is warranted.
• This review provides a foundation for advancing selenized microtubule-targeted therapies.